Pfizer raises earnings guidance after 'solid' third quarter results

Pfizer on Tuesday released an updated earnings guidance met to reflect what it said was strong performance in the third quarter of 2022 including marked year-over-year growth. 

The company said in a press release that it was upping its earnings-per-share estimate from a maximum of $6.45 to $6.50. It reported a 6% growth in revenue year-over-year for the quarter. 

Nine-month revenue compared to last year saw an even bigger leap, jumping 32% for a total of around $7.6 billion.

CEO Albert Bourla said in the release that the company saw success in part from the continued development of an "RSV vaccine candidate for older adults and for infants through maternal vaccination" as well as a "meningococcal vaccine candidate for adolescents and young adults."